Following a re-evaluation, the EMA has recommended Eisai and Biogen’s Alzheimer’s therapy Leqembi for a subgroup of patients.

Europe's medicines watchdog on Thursday partially approved a marketing request for a long-awaited new treatment for Alzheimer ...

Galantamine slowed decline in cognitive function, functional ability, and behavior at 6 months in people with Alzheimer's ...

The capabilities of artificial intelligence continue to advance rapidly, and the medical field is no exception.Baptist Health ...

A new interdisciplinary study at the University of Delaware seeks to study AD by examining changes in the arteries and brain ...

Study finds mosaicism in Down syndrome reduces Alzheimer's risk, providing new insights into genetic influences on cognitive ...

Upon reexamination, the European Medicines Agency has made a U-turn on Eisai and Biogen’s Alzheimer’s disease drug Leqembi. | ...

As technology continues to advance, I’m excited for the future of radiology and the enhanced care it will bring to patients.” ...

BIDMC is one of the award recipients for the ARPA-H Sprint for Women’s Health, and will use it to assess brain disorders in women. Learn about the project.

Researchers developed an AI-based deep learning model that uses retinal images to detect early-stage Alzheimer's disease and ...